Subclinical hyperthyroidism is a condition where your thyroid is slightly overactive, but not enough to push thyroid hormone levels outside the normal range. It shows up on blood work as a low TSH (the hormone that tells your thyroid to work) while your actual thyroid hormones remain normal. About 1 to 3% of the general population has it, with rates climbing to nearly 6% in some older populations.
The condition often produces no obvious symptoms, which is why “subclinical” is in the name. But that doesn’t mean it’s harmless. Over time, even mildly suppressed TSH raises the risk of heart rhythm problems, bone loss, and progression to full-blown hyperthyroidism.
How It Shows Up on Blood Work
A normal TSH falls between roughly 0.45 and 4.5 μU/mL. In subclinical hyperthyroidism, TSH drops below 0.45 while free T4 and T3 stay within their normal ranges. That’s the key distinction from overt hyperthyroidism, where thyroid hormones themselves are elevated.
Doctors classify the condition into two grades based on how low TSH falls:
- Grade I (mild): TSH between 0.1 and 0.4 μU/mL
- Grade II (severe): TSH below 0.1 μU/mL
This distinction matters because the risks and treatment recommendations differ significantly between the two. In some cases, free T4 is normal but T3 runs slightly high, a pattern sometimes called T3-toxicosis. This can be an early sign of a thyroid nodule that’s producing hormones on its own.
What Causes It
The causes fall into two broad categories: something your own thyroid is doing (endogenous) or something caused by medication (exogenous).
Endogenous causes include Graves’ disease, where the immune system stimulates the thyroid, and toxic multinodular goiter, where one or more thyroid nodules produce hormones independently. These are the same conditions that cause overt hyperthyroidism; they’re just caught at an earlier, milder stage.
Exogenous subclinical hyperthyroidism is actually the more common form, and it happens when someone taking thyroid hormone replacement (levothyroxine) ends up on a dose that’s slightly too high. A population-based study in Germany found that among people taking levothyroxine, roughly 18% were overtreated, meaning their TSH was suppressed below the normal range. Sometimes this oversuppression is intentional, as in thyroid cancer patients whose doctors want to keep TSH low. But often it’s simply a dosing issue that hasn’t been caught.
Symptoms You Might Notice
Many people with subclinical hyperthyroidism feel completely fine, which is why the condition is usually discovered incidentally during routine bloodwork. But “subclinical” can be misleading. Some people do experience symptoms, and studies show that quality of life scores in these patients are measurably worse than in the general population.
The symptoms that tend to surface are subtle versions of what you’d see in overt hyperthyroidism: fatigue, anxiety, difficulty concentrating, emotional ups and downs, and a general sense of restlessness or agitation. Tiredness is one of the most commonly reported complaints, which can seem counterintuitive for a condition involving an overactive thyroid. Sleep disruption and a slightly faster resting heart rate can also occur. Because these symptoms overlap with so many other conditions (stress, poor sleep, perimenopause), they’re easy to dismiss or attribute to something else entirely.
Risks to Your Heart
The most significant concern with subclinical hyperthyroidism is its effect on the heart, particularly the risk of atrial fibrillation, an irregular heart rhythm that can lead to blood clots and stroke. Studies have found that people with subclinical hyperthyroidism face anywhere from 1.7 to 3.1 times the risk of developing atrial fibrillation compared to people with normal thyroid function. That’s a substantial increase, especially for older adults who already carry higher baseline cardiovascular risk.
Even without atrial fibrillation, the mildly elevated thyroid activity can increase heart rate, raise blood pressure slightly, and over years contribute to changes in heart structure. The more suppressed the TSH and the longer the condition persists, the greater these cardiovascular effects become.
Effects on Bone Density
Thyroid hormones play a direct role in bone turnover, the cycle of breaking down old bone and building new. When thyroid activity runs even slightly high for a prolonged period, the breakdown side of that equation speeds up. A large analysis published in JAMA Network Open found that people with subclinical hyperthyroidism had a 34% higher risk of fracture compared to those with normal thyroid function.
This is especially relevant for postmenopausal women, who are already losing bone density due to declining estrogen. For this group, untreated subclinical hyperthyroidism compounds an existing vulnerability. The risk appears to increase as TSH drops further below normal.
Who Gets Treated and Who Gets Monitored
Whether subclinical hyperthyroidism needs treatment depends on the grade, your age, and whether you have other health conditions. The general approach breaks down like this:
For Grade II (TSH below 0.1), treatment is typically recommended, particularly for people over 65 or those with heart disease, osteoporosis, or symptoms affecting daily life. The cardiovascular and bone risks at this level of TSH suppression are well established enough that most guidelines favor intervention.
For Grade I (TSH between 0.1 and 0.4), the picture is less clear-cut. In older adults with existing heart problems or low bone density, treatment may still be warranted. In younger, otherwise healthy people, monitoring without treatment is often the initial approach because mild cases sometimes resolve on their own, especially if the cause is temporary thyroiditis.
If the cause is exogenous (too much levothyroxine), the fix is straightforward: reducing the dose. This is the simplest scenario, but it requires that the oversuppression actually gets flagged, which means regular blood work. For endogenous causes like Graves’ disease or toxic nodules, treatment options parallel those for overt hyperthyroidism: antithyroid medications, radioactive iodine, or surgery, depending on the underlying condition.
What Monitoring Looks Like
If your doctor decides to watch rather than treat, that means periodic TSH testing to see whether the condition resolves, stays stable, or progresses toward overt hyperthyroidism. Testing every 3 to 6 months is common in the early period after diagnosis. If TSH remains stable in the mildly low range over time, testing intervals may stretch out.
The key thing being tracked is whether your TSH drops further (suggesting progression) or drifts back into the normal range (suggesting a transient cause). If you’re in the monitoring category, it’s also worth paying attention to symptoms like a noticeable increase in heart rate, unexplained weight loss, tremor, or worsening anxiety, as these could signal a shift toward overt disease that warrants retesting sooner.